Display options
Cite
Shenghua P, Shuyu T, Kunping L, et al. UPLC-QTOF/MS-Based Lipidomic Profiling of Liver Qi-Stagnation and Spleen-Deficiency Syndrome in Patients with Hyperlipidemia. Evid Based Complement Alternat Med. 2018;2018:4530849doi: 10.1155/2018/4530849.
Shenghua, P., Shuyu, T., Kunping, L., Huixia, Z., Xue, X., & Jiao, G. (2018). UPLC-QTOF/MS-Based Lipidomic Profiling of Liver Qi-Stagnation and Spleen-Deficiency Syndrome in Patients with Hyperlipidemia. Evidence-based complementary and alternative medicine : eCAM, 20184530849. https://doi.org/10.1155/2018/4530849
Shenghua, Piao, et al. "UPLC-QTOF/MS-Based Lipidomic Profiling of Liver Qi-Stagnation and Spleen-Deficiency Syndrome in Patients with Hyperlipidemia." Evidence-based complementary and alternative medicine : eCAM vol. 2018 (2018): 4530849. doi: https://doi.org/10.1155/2018/4530849
Shenghua P, Shuyu T, Kunping L, Huixia Z, Xue X, Jiao G. UPLC-QTOF/MS-Based Lipidomic Profiling of Liver Qi-Stagnation and Spleen-Deficiency Syndrome in Patients with Hyperlipidemia. Evid Based Complement Alternat Med. 2018 Aug 30;2018:4530849. doi: 10.1155/2018/4530849. eCollection 2018. PMID: 30245731; PMCID: PMC6136559.
Copy Download .nbib Format: NLM
Share it on

Evid Based Complement Alternat Med. 2018 Aug 30;2018:4530849. doi: 10.1155/2018/4530849. eCollection 2018.

UPLC-QTOF/MS-Based Lipidomic Profiling of Liver Qi-Stagnation and Spleen-Deficiency Syndrome in Patients with Hyperlipidemia.

Evidence-based complementary and alternative medicine : eCAM

Piao Shenghua, Tan Shuyu, Li Kunping, Zhan Huixia, Xiao Xue, Guo Jiao

Affiliations

  1. Key Unit of Modulating Liver to Treat Hyperlipemia SATCM (State Administration of Traditional Chinese Medicine), Guangdong Pharmaceutical University, Guangzhou Higher Education Mega Centre, Guangzhou 510006, China.
  2. Guangdong TCM Key Laboratory against Metabolic Diseases, Guangdong Pharmaceutical University, Guangzhou Higher Education Mega Centre, Guangzhou 510006, China.
  3. Guangdong Province Research Centre for Chinese Integrative Medicine against Metabolic Disease, Guangdong Pharmaceutical University, Guangzhou Higher Education Mega Centre, Guangzhou 510006, China.

PMID: 30245731 PMCID: PMC6136559 DOI: 10.1155/2018/4530849

Abstract

Hyperlipidemia is a common disease caused by abnormal plasma lipid metabolism. Lipidomics is a powerful and efficient technology to study the integration of disease and syndrome of Chinese medicine. This study investigated specific changes in lipid metabolites from hyperlipidemia patients with syndrome of liver qi-stagnation and spleen-deficiency (SLQSD). Lipid profiles in plasma samples from 29 hyperlipidemia patients including 10 SLQSD and 19 non-SLQSD and 26 healthy volunteers (NC) were tested by UPLC-QTOF/MS. PLS-DA analysis and database searching were performed to discover differentiating metabolites. Differences in lipid metabolites between hyperlipidemia and healthy people mainly include phosphatidylcholines, phosphatidylethanolamines, phosphatidylglycerols, and ceramides. Hyperlipidemia patients with SLQSD and non-SLQSD could be differentiated by using identified lipid metabolites including phosphatidylcholines, phosphatidylethanolamines, phosphatidylinositols, triglycerides, diacylglycerols, lysophosphatidylethanolamines, sphingomyelins, lysophosphatidylcholines, and lactosylceramides. There were significant differences of lipid metabolism between between different syndromes of the same disease such as hyperlipidemia which showed significant differences between SLQSD and non-SLQSD.

References

  1. J Pharm Biomed Anal. 2018 Jul 15;156:104-115 - PubMed
  2. Phytochemistry. 2018 Feb;146:56-62 - PubMed
  3. J Ethnopharmacol. 2012 Apr 10;140(3):634-42 - PubMed
  4. Mediators Inflamm. 2015;2015:120748 - PubMed
  5. Chem Phys Lipids. 2018 Aug;214:69-83 - PubMed
  6. Chem Biol Interact. 2014 Sep 5;220:181-92 - PubMed
  7. J Biol Chem. 2009 Dec 4;284(49):33833-40 - PubMed
  8. Phytomedicine. 2018 Mar 15;42:207-218 - PubMed
  9. J Ethnopharmacol. 2018 Jun 12;219:299-318 - PubMed
  10. Chem Biol Interact. 2017 Aug 1;273:133-141 - PubMed
  11. PLoS One. 2012;7(7):e41456 - PubMed
  12. Redox Biol. 2017 Aug;12:505-521 - PubMed
  13. J Ethnopharmacol. 2011 Apr 12;134(3):584-607 - PubMed
  14. J Agric Food Chem. 2016 Feb 3;64(4):969-79 - PubMed
  15. Phytother Res. 2012 Oct;26(10):1466-71 - PubMed
  16. Chem Biol Interact. 2016 May 25;252:114-30 - PubMed
  17. Crit Rev Biochem Mol Biol. 2013 Jan-Feb;48(1):20-38 - PubMed
  18. Clin Biochem. 2014 Oct;47(15):16-26 - PubMed
  19. Redox Biol. 2016 Dec;10:168-178 - PubMed
  20. J Proteome Res. 2015 Jun 5;14(6):2367-84 - PubMed
  21. Clin Chim Acta. 2012 Oct 9;413(19-20):1438-45 - PubMed
  22. Chem Biol Interact. 2015 Oct 5;240:220-38 - PubMed
  23. Talanta. 2011 Jan 15;83(3):700-8 - PubMed
  24. Pharm Biol. 2018 Dec;56(1):145-153 - PubMed
  25. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2012 Oct;32(10):1322-5 - PubMed
  26. J Anal Methods Chem. 2014;2014:184162 - PubMed
  27. Chin Med J (Engl). 2016 May 5;129(9):1078-86 - PubMed
  28. Phytomedicine. 2017 Dec 1;36:243-253 - PubMed
  29. Nephrol Dial Transplant. 2017 Jul 1;32(7):1154-1166 - PubMed
  30. Subcell Biochem. 2014;77:41-8 - PubMed
  31. Nat Rev Mol Cell Biol. 2011 Sep 14;12(10):674-9 - PubMed
  32. J Proteome Res. 2017 Apr 7;16(4):1566-1578 - PubMed
  33. J Cell Mol Med. 2010 Dec;14(12):2721-8 - PubMed
  34. Phytomedicine. 2014 Sep 25;21(11):1364-72 - PubMed
  35. Sci Rep. 2016 Feb 23;6:22151 - PubMed
  36. J Nutr Biochem. 2015 Jul;26(7):687-95 - PubMed
  37. Biomark Med. 2015;9(2):153-68 - PubMed
  38. Chem Biol Interact. 2015 Feb 25;228:79-87 - PubMed
  39. Am J Physiol Gastrointest Liver Physiol. 2016 May 1;310(9):G629-44 - PubMed
  40. Evid Based Complement Alternat Med. 2012;2012:120350 - PubMed
  41. Sci Rep. 2015 Aug 07;5:12936 - PubMed
  42. J Agric Food Chem. 2018 Feb 28;66(8):1828-1842 - PubMed
  43. Int Rev Cell Mol Biol. 2014;313:1-26 - PubMed

Publication Types